89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023
06/07/2023 - 08:00 AM
SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria. The presentation was selected for inclusion in the Best of EASL Congress summary slide deck that highlights the most noteworthy contributions to the scientific program at EASL.
Details for the late-breaker oral presentation are as follows:
Abstract Title: Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)Abstract Number: LBO-05Format: Oral presentationPresenting Author: Rohit Loomba, M.D., MHSc, Director, NAFLD Research Center, University of California San Diego, and lead investigator of ENLIVENPresentation Date and Time: Saturday, June 24th 12:00-12:15 CET
89bio will also present data from a preclinical study. Presentation details are as follows:
Abstract Title: Pegozafermin inhibits NASH-induced hepatocellular carcinoma in the STAM™ mouse modelAbstract Number: SAT-243Format: Poster Presenting Author: Maya Margalit, M.D., of 89bio Presentation Date and Time: Saturday, June 24th 9:00-17:00 CET
About 89bio 89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead therapeutic candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn .
Investor Contact: Ryan Martins Chief Financial Officer investors@89bio.com
PJ Kelleher LifeSci Advisors, LLC +1-617-430-7579 pkelleher@lifesciadvisors.com
Media Contact: Sheryl Seapy Real Chemistry sseapy@realchemistry.com
ETNB Rankings
#3848 Ranked by Stock Gains
ETNB Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
About ETNB
89bio, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. its lead product candidate is bio89-100, a glycopegylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. the company also intends to develop bio89-100 for the treatment of severe hypertriglyceridemia. 89bio, inc. was founded in 2018 and is based in san francisco, california.